SCHEMBL2184766

SCHEMBL2184766

CCOC(=O)C(C#N)c1cc(Cl)cc(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GPR35 Q9HC97 2/20 0.40
BCL2 P10415 1/20 0.36
HTT P42858 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 2/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MAOB P27338 1/20 0.34
GPR139 Q6DWJ6 1/20 0.34
POLB P06746 1/20 0.33
PTP4A1 Q93096 1/20 0.33
ABCB1 P08183 1/20 0.33
MMP8 P22894 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2182424 0.86 MEN1 (0.45) MEN1KMT2AGAASMN1; SMN2GPR35
SCHEMBL2186292 0.80 NOTUM (0.45) MEN1KMT2AGAASMN1; SMN2GPR35
SCHEMBL137527 0.80 GPR35 (0.43) MEN1KMT2ASMN1; SMN2GPR35HTT
SCHEMBL3270887 0.79 GAA (0.50) MEN1KMT2AGAASMN1; SMN2ALDH1A1
SCHEMBL13700788 0.78 KMT2A (0.51) MEN1KMT2AGAASMN1; SMN2BCL2
SCHEMBL5081149 0.78 SMN1; SMN2 (0.51) MEN1KMT2AGAASMN1; SMN2ALDH1A1
SCHEMBL153724 0.77 MMP8 (0.42) MEN1KMT2ASMN1; SMN2GPR35HTT
SCHEMBL22995350 0.77 KMT2A (0.57) MEN1KMT2AGAASMN1; SMN2GPR35
SCHEMBL17466005 0.75 MEN1 (0.58) MEN1KMT2AGAASMN1; SMN2HTT
SCHEMBL15475549 0.75 KMT2A (0.48) MEN1KMT2AGAASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022204150-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS BLUE OAK PHARMACEUTICALS, INC. (US) 2022-09-29 WO disclosed
US-20110166132-A1 Gamma Secretase Modulators AMGEN INC. (US) 2011-07-07 US disclosed
EP-2231602-A1 GAMMA SECRETASE MODULATORS Amgen, Inc (US) 2010-09-29 EP disclosed
WO-2009075874-A1 GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166132-A1 Gamma Secretase Modulators BACE1, BACE2, PSEN1 MEN1 2950/4885KMT2A 3574/4885GAA 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.